ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
04/24/2026
Back to search
Official data from USPTO
ALKERMES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ALKERMES
ST13
US500000088788969Class
5, 35, 36, 44, 45
Filing
88788969
Registration
6925355
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
04/25/2026
Trademark type
Word
Nice classes
5, 35, 36, 44, 45
Filing date
02/07/2020
Registration date
12/13/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/13/2022
Last transaction
04/25/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/21/2022
First use in commerce
01/21/2022
Drawing code
4
Owner type
03
Owner location
Waltham, MA, US
Examiner
DANG, PETER T
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Alkermes, Inc.
Representatives
Norm J. Rich FOLEY & LARDNER LLP
Technical classification
Nice Classes
Class 5Class 35Class 36Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationscompounds for use in treating addictionsubstance abuse and dependencediseases and disorders of the central nervous systemcancerreward disorderspsychiatric and neurodegenerative diseases and disorders in the nature of schizophreniadepressionmajor depressive disorderstressanxietytreatment resistant depressionbipolar depressionbipolar disorder; pharmaceutical preparations for use in treating cardiovascular diseases and metabolic diseases; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidaemia; Pharmaceutical preparationsprodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorderspsychiatric and neurodegenerative diseasescardiovascular diseases and metabolic diseases; pharmaceutical preparations in the nature of compoundssmall molecules and chemical compounds for use in opioid modulation for treating opioid use disorders
Class 35
Administration and management of an annual competitive award program in the nature of research grants for scientific research; Logistics management in the field of medicationbusiness services in the nature of supporting the coordination of medication delivery to avoid product delivery delays; providing business administration information to patients and health care providers about medication reimbursement options regarding reimbursement procedures; providing information about pharmaceutical servicesproviding information about processing online prescription orders in retail pharmacies regarding pharmacy authorization in the nature of prescription fulfillment and approval instructions for delivery of medication in the nature of accepting payment terms; appointment reminder services being support services for patients and for health care providers on behalf of their patients
Class 36
Providing grants to organizations dedicated to patient focused medical research; funding service awardsproviding grants to patient advocacy groups and institutions for the treatment and management of diseases includingbut not limited toaddiction and central nervous system disorders; Providing insurance information about pharmaciesproviding a database featuring information about insurance coverage for pharmaceuticals in the nature of pharmacy selection based on patient health plan coverage requirements; providing insurance information about pharmaceutical coverage by patient health plans; providing insurance administration information to patients and health care providers about medication reimbursement options; insurance servicesinsurance eligibility review and verification being support services for patients and for health care providers on behalf of their patientsproviding health benefit verification services to determine coverage of medication treatment in the health industry; financial administration of medication reimbursement programs being support services for patients and for health care providers on behalf of their patientscoordinating medication reimbursement programs
Class 44
Providing educational information in the field of medication treatment to health care providers and patients; providing educational information about pharmaceutical products relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals
Class 45
Support services for health care providers and their patients in the nature of providing patient advocate and case management servicescoordinating the procurement of medication in the nature of coordinating with pharmacies to facilitate prescription fulfillment; providing patient advocate and case management services in the nature of support services for patients and for health care providers on behalf of their patientscoordinating the procurement and administration of medication in the nature of locating health care providers that can prescribe and/or administer prescribed medication
Publications
History of USPTO decisions and trademark events.
39 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/13/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
12/13/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/09/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/08/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/08/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/07/2022
EX4G
SOU EXTENSION 4 GRANTED
11/07/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/07/2022
IUAF
USE AMENDMENT FILED
10/28/2022
EXT4
SOU EXTENSION 4 FILED
10/28/2022
EEXT
SOU TEAS EXTENSION RECEIVED
10/28/2022
EISU
TEAS STATEMENT OF USE RECEIVED
10/28/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/07/2022
EX3G
SOU EXTENSION 3 GRANTED
05/05/2022
EXT3
SOU EXTENSION 3 FILED
05/05/2022
EEXT
SOU TEAS EXTENSION RECEIVED
05/05/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/18/2021
EX2G
SOU EXTENSION 2 GRANTED
11/16/2021
EXT2
SOU EXTENSION 2 FILED
11/16/2021
EEXT
SOU TEAS EXTENSION RECEIVED
11/16/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/01/2021
EX1G
SOU EXTENSION 1 GRANTED
04/29/2021
EXT1
SOU EXTENSION 1 FILED
04/29/2021
EEXT
SOU TEAS EXTENSION RECEIVED
04/29/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/17/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/22/2020
PUBO
PUBLISHED FOR OPPOSITION
09/22/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/17/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/06/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/06/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/28/2020
GNRT
NON-FINAL ACTION E-MAILED
04/28/2020
CNRT
NON-FINAL ACTION WRITTEN
04/28/2020
DOCK
ASSIGNED TO EXAMINER
04/28/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/11/2020
NWAP
NEW APPLICATION ENTERED
02/11/2020
Continuous trademark protection
Get notified about every new filing that threatens ALKERMES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.